To the knowledge of the present authors, this study is the first of its kind to explore the lived experiences (i.e., from diagnosis throughout the treatment trajectory) specifically of women diagnosed with non-metastatic HER2 + breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.